PS
AMRX icon

Principal Securities’s Amneal Pharmaceuticals AMRX Stock Holding History

Principal Securities’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$427K Buy
24,678
+14,135
+134% +$194K 0.01% 1153
2026
Q1 		$131K Buy
+10,543
New +$142K ﹤0.01% 1401
2025
Q4 		– Sell
-2,170
Closed -$21.7K – 1437
2025
Q3 		$21.7K Buy
+2,170
New +$19.5K ﹤0.01% 2367

Other funds holding AMRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Principal Securities's AMRX Position: Q2 2026 in Review

Principal Securities increased its Amneal Pharmaceuticals (AMRX) stake by 134% in Q2 2026, buying an estimated $194K and bringing the position to 24,678 shares worth $427K. The position accounts for 0.01% of the portfolio, ranked #1153.

Principal Securities first reported a position in AMRX in Q3 2025 and has held it in 3 quarters since. 310 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

  • Principal Securities held 24,678 shares of Amneal Pharmaceuticals worth $427K as of Q2 2026.
  • Principal Securities bought 14,135 Amneal Pharmaceuticals shares in Q2 2026, an estimated $194K.
  • Amneal Pharmaceuticals made up 0.01% of Principal Securities's portfolio in Q2 2026, its #1153 holding.
  • Principal Securities first reported a position in Amneal Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • 310 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on Principal Securities's 13F filing for Q2 2026, filed 4 Aug 2026.